Drug‐Induced Liver Injury Associated With Moxifloxacin: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System and a Real‐World Retrospective Study
Basic & Clinical Pharmacology & Toxicology · 2026
DOI: 10.1111/bcpt.70187 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2026. Verfasst von Yanqing Song und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Lequn Branch, the First Hospital of Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Chemical and Drug Induced Liver Injury, Moxifloxacin, Anti-Bacterial Agents. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Talent Reserve Program (TRP) of The First Hospital of Jilin University, Wu Jieping Medical Foundation.
Abstract (Originalsprache)
Objective
While current studies have focused on the incidence of moxifloxacin‐associated liver injury, risk factors and clinical characteristics for moxifloxacin‐induced liver injury in hospitalized patients remain unexplored.
Methods
We analysed antibiotic‐induced liver injury using the US Food and Drug Administration Adverse Event Reporting System (FAERS) database. A retrospective observational study was further conducted on 1265 hospitalized patients treated with moxifloxacin for infections. Independent risk factors for moxifloxacin‐induced DILI were identified via multivariable logistic regression.
Results
FAERS data indicated that moxifloxacin‐induced liver injury exacerbates clinical outcomes, prolongs hospitalization, and may be life‐threatening. Infections were the primary indication for fluoroquinolone use, with gender‐specific differences observed in liver injury profiles across quinolones. Retrospective analyses revealed gender as an independent protective factor ( p = 0.003). Risk factors included hypoalbuminemia ( p = 0.003), hepatic comorbidities (fatty liver, p = 0.013; pre‐existing liver injury, p < 0.013), elevated baseline alkaline phosphatase (ALP, p < 0.001) and concomitant use of traditional Chinese medicine or respiratory drugs ( p < 0.001).
Conclusion
Despite widespread clinical use, moxifloxacin's safety profile requires systematic evaluation. Clinicians should monitor liver function and integrate risk stratification, including albumin levels, gender and concomitant medications into prescribing practices. Elucidating DILI mechanisms and high‐risk populations may optimize therapeutic decision‐making and patient safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Lequn Branch, the First Hospital of Jilin University, Changchun, China.
- Jilin Medical Association Secretariat, Changchun, China.
- Department of Clinical Pharmacy, the First Hospital of Jilin University, Changchun, China.
ORCID-Profile: Huan Gao
Förderung
- Talent Reserve Program (TRP) of The First Hospital of Jilin University
- Wu Jieping Medical Foundation
Zitieren
APA
Song, Y., Li, C., Liu, X., & Gao, H. (2026). Drug‐Induced Liver Injury Associated With Moxifloxacin: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System and a Real‐World Retrospective Study. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70187
Vancouver
Song Y, Li C, Liu X, Gao H. Drug‐Induced Liver Injury Associated With Moxifloxacin: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System and a Real‐World Retrospective Study. Basic & Clinical Pharmacology & Toxicology. 2026. doi:10.1111/bcpt.70187
BibTeX
@article{Song2026,
author = {Song, Yanqing and Li, Chunzi and Liu, Xiaoyue and Gao, Huan},
title = {Drug‐Induced Liver Injury Associated With Moxifloxacin: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System and a Real‐World Retrospective Study},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2026},
doi = {10.1111/bcpt.70187}
}
EUVIMED